Prior to initiating ONTRUZANT:
Recommended dosage
aWithin 3 weeks following completion of all chemotherapy.
HER2+, human epidermal growth factor receptor 2-positive; min, minutes; QW, once a week; Q3W, once every 3 weeks.
150 mg Single-dose vial | ONTRUZANT (trastuzumab-dttb) for injection 150 mg/vial is supplied in a single-dose vial as a white to pale yellow lyophilized sterile powder, under vacuum. Each carton contains one single-dose vial of ONTRUZANT. | NDC 78206-147-01 |
420 mg Multiple-dose vial | ONTRUZANT (trastuzumab-dttb) for injection 420 mg/vial is supplied in a multiple-dose vial as a white to pale yellow lyophilized sterile powder, under vacuum. Each carton contains one multiple-dose vial of ONTRUZANT and one vial (20 mL) of Bacteriostatic Water for Injection (BWFI), USP, containing 1.1% benzyl alcohol as a preservative. | NDC 78206-148-01 |
HERCEPTIN is a trademark registered in the US by Genentech, Inc.; Organon is not associated with this trademark owner.
ONTRUZANT is indicated in adults for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature) breast cancer:
Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.
ONTRUZANT is indicated in adults:
Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.
ONTRUZANT is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.
Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.
ER = estrogen receptor
HER2 = human epidermal growth factor receptor 2
PR = progesterone receptor
MUGA = multigated acquisition
NCI-CTC = National Cancer Institute-Common Terminology Criteria
PK = pharmacokinetics
Before prescribing ONTRUZANT, please read the accompanying Prescribing Information, including the Boxed Warning about cardiomyopathy, infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.